Zhonghua Xue Ye Xue Za Zhi is a peer-reviewed journal and the definitive journal for Chinese scientists, clinicians, and trainees in the field of Hematology. and the inaugural issue debuted on February 14, 1980. is a member of Chinese Medical Association (CMA).
 

Journal Frequency and Access. Zhonghua Xue Ye Xue Za Zhi is published print and online monthly, and in 12 print/online issues a year. The journal receives over 0.37 million online visits annually and more than 0.68 million article views and downloads. All research articles are made free access online immediately.

Editorial Information. The journal’s acceptance rate is 23%. The median time to first decision is 3 days, and 45 days with review. The journal's Institute of Scientific and Technical Information of China (ISTIC) Impact Factor is 1.227, the highest ranking among hematology journals in China. All articles are published online first. Additional information on the types of articles published and editorial policies is available in the journal's Instructions for Authors.

Editorial Team. The Editor in Chief of Zhonghua Xue Ye Xue Za Zhi is Xiaojun Huang (黄晓军), MD. Dr Huang is director of the Peking University Institute of Hematology and Peking University People’s Hospital. For a complete listing of the journal's Editors and Editorial Board, see Editors and Publishers.

Mission Statement. Zhonghua Xue Ye Xue Za Zhi is committed to publishing influential original research, opinions, and reviews that advance the science of oncology and improve the clinical care of patients with hematology. Our original, innovative, and timely scientific and educational content provides a deeper understanding of cancer pathogenesis and recent treatment advances for our readers. JAMA Oncology aims to effectively convey the findings of important clinical research, major scientific breakthroughs, actionable discoveries, and state-of-the-art treatment pathways to the oncology community. Our goal is that successful communication of new knowledge will ultimately translate to clinical benefit for people living with and surviving cancer.

free access statement. Zhonghua Xue Ye Xue Za Zhi is fully free access journal, which means that all articles are available on the internet to all users immediately upon publication. Non-commercial use and distribution in any medium is permitted, provided the author and the journal are properly credited.

Disclaimer. The ideas and opinions expressed in Zhonghua Xue Ye Xue Za Zhi do not necessarily reflect those of the CMA or the Editors of Zhonghua Xue Ye Xue Za Zhi. Publication of an advertisement or other product mention in Zhonghua Xue Ye Xue Za Zhi should not be construed as an endorsement of the product or the manufacturer's claims. Readers are encouraged to contact the manufacturer with any questions about the features or limitations of the products mentioned. Zhonghua Xue Ye Xue Za Zhi does not assume any responsibility for any injury and/or damage to persons or property arising from or related to any use of the material contained in this periodical. The reader is advised to check the appropriate medical literature and the product information currently provided by the manufacturer of each drug to be administered to verify the dosage, the method and duration of administration, or contraindications. It is the responsibility of the treating physician or other health care professional, relying on his or her independent experience and knowledge of the patient, to determine drug dosages and the best treatment for the patient.

Zhonghua Xue Ye Xue Za Zhi

ISSN 0253-2727 (Print)

ISSN 2707-9740 (Online)

CN 12-1090/R

Contant Us

Tell: 86-22-27304167

Email: zhxyx@hematoline.com

Web: www.hematoline.com